<DOC>
	<DOCNO>NCT02921178</DOCNO>
	<brief_summary>The purpose study effect Omalizumab compare non-Omalizumab treatment propensity-matched group asthma exacerbation asthma patient Korea : retrospective cohort real world . Omalizumab approve 2007 Korea use center . We would like collect analyze data exacerbation outcomes patient Omalizumab ; Korean real world data available .</brief_summary>
	<brief_title>Effects Omalizumab Compared Non-Omalizumab Treatment Asthma Patients</brief_title>
	<detailed_description>1 . Primary secondary outcome analysis method ( 1 ) Primary endpoint Comparison asthma exacerbation rate omalizumab-treated vs non-Omalizumab treat group outcome period ( 6 month ) . ( asthma exacerbation : least 1 systemic steroid treatment and/or burst systemic oral steroid use prednisone-equivalent dose ≥45mg/3days , 6 month relieve asthma exacerbation . ) Fisher 's exact test examine asthma exacerbation omalizumab-treated vs non-Omalizumab treat group . ( 2 ) Secondary endpoint - Comparison clinical parameter Asthma exacerbation rate , ICS spar effect , OCS requirement , lung function ( FEV1 % ) , Healthcare resource use ( asthma-related ER visit/hospitalization ) 1 . Within Omalizumab-treated group baseline outcome period 2 . Between Omalizumab-treated not-treated group outcome period For comparison within group , pair T-test McNemar test apply continuous categorical parameter , respectively . And , T-test Fisher 's exact test examine continuous categorical parameter Omalizumab-treated not-treated group . Incidentally , non-parametric test examine need . - Finding predictor favorable responder Omalizumab 6 month . ( Favorable responder : 50 % reduction asthma exacerbation steroid requirement 6 month with/without ICS/LABA ) Candidate factor : Omalizumab treatment period/monthly dose , age , gender , asthma treatment duration , total IgE , sputum cell profile , peripheral eosinophilia serum periostin level , anti-asthmatic drug requirement etc . Binary logistic regression use find predictor favorable responder . If serious imbalance dependent parameter occur low frequency favorable responder , descriptive analysis apply T-test Fisher 's exact test .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>1 . Codes asthma ( ICD10 : J45 ) dependent availability Who diagnose allergic asthma asthma exacerbation ( J45 asthma , J45.0 predominantly allergic asthma J45.8 mixed asthma ) Those initially diagnosed J45.9 asthma , unspecified , refer evidence allergic component IgE level skin prick test result . 2 . Aged 1880 year index date 3 . Active asthma , define ≥ 1 prescription LABA/ICS baseline period 4. uncontrolled asthma baseline period Any one three criterion A . Asthma exacerbation B. Asthmarelated ER visit/Hospitalization C. Physician define uncontrolled asthma Worsening symptom status Worsens taper high dose ICS systemic CS Air flow limitation ( appropriate bronchodilator withhold FEV1 % &lt; 80 % predict ) take biologics baseline outcome period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>